aTYR PHARMA INC
ATYRaTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
28dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ATYR1940 | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in aTYR PHARMA INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in aTYR PHARMA INC's (ATYR) pipeline across Phase 2. Its lead program is ATYR1940 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is aTYR PHARMA INC's next FDA catalyst?→
aTYR PHARMA INC's (ATYR) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATYR biotech catalysts?→
Add ATYR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow aTYR PHARMA INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.